Skip to main content

Table 2 Univariate Cox proportional hazards regression analysis for overall survival and relapse-free survival in gallbladder carcinoma patients

From: Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma

Characteristics

No.

OS

p

RFS

p

HR (95% CI)

HR (95% CI)

Age, y ≥ 65 (vs. <  65)

50/105

2.720 (1.655–4.470)

<  0.001

2.600 (1.592–4.245)

<  0.001

Sex, female (vs. male)

50/105

0.853 (0.529–1.376)

0.516

0.796 (0.495–1.280)

0.347

CEA, elevated (vs. normal)

19/105

1.284 (0.701–2.352)

0.419

1.194 (0.653–2.185)

0.564

CA19–9, elevated (vs. normal)

34/105

1.864 (1.143–3.040)

0.013

1.809 (1.112–2.942)

0.017

TNM stage

 I

25/105

1

<  0.001

1

<  0.001

 II

37/105

2.459 (1.094–5.529)

0.030

2.619 (1.170–5.862)

0.019

 III

31/105

5.495 (2.466–12.247)

<  0.001

5.129 (2.300–11.436)

<  0.001

 IV

12/105

18.262 (6.941–48.048)

<  0.001

16.700 (6.374–43.750)

<  0.001

T category

 T1

26/105

1

<  0.001

1

<  0.001

 T2

50/105

2.954 (1.358–6.425)

0.006

3.051 (1.406–6.622)

0.005

 T3

25/105

10.560 (4.641–24.030)

<  0.001

9.672 (4.252–22.004)

<  0.001

 T4

4/105

11.670 (3.379–40.309)

<  0.001

12.256 (3.542–42.413)

<  0.001

LN metastasis, presence (vs. absence)

26/105

2.019 (1.207–3.376)

0.007

1.898 (1.137–3.168)

0.014

Distant metastasis, presence (vs. absence)

7/105

7.082 (2.971–16.885)

<  0.001

5.419 (2.339–12.555)

<  0.001

Lymphovascular invasion, presence (vs. absence)

10/105

3.166 (1.551–6.465)

0.002

2.886 (1.416–5.881)

0.004

Histologic type

 adenocarcinoma NOS

101/105

1

0.003

1

0.005

 adenosquamous carcinoma

3/105

4.268 (1.320–13.800)

0.015

3.587 (1.113–11.563)

0.032

 squamous cell carcinoma NOS

1/105

15.503 (1.903–126.302)

0.010

15.437 (1.894–125.789)

0.011

Histologic grade, high (vs. low)

62/105

3.197 (1.855–5.510)

<  0.001

2.989 (1.753–5.097)

<  0.001

cytoplasmic ZNF16, positive (vs. negative)

40/105

1.675 (1.038–2.703)

0.035

1.557 (0.968–2.505)

0.068

nuclear ZNF16, positive (vs. negative)

60/105

3.287 (1.888–5.722)

<  0.001

3.038 (1.765–5.229)

<  0.001

cytoplasmic FAM83H, positive (vs. negative)

34/105

2.292 (1.413–3.720)

<  0.001

2.201 (1.360–3.564)

0.001

nuclear FAM83H, positive (vs. negative)

49/105

2.823 (1.716–4.646)

<  0.001

2.685 (1.640–4.395)

<  0.001

  1. Abbreviations: OS overall survival, RFS relapse-free survival, HR hazard ratio, 95% CI 95% confidence interval, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, LN lymph node, NOS not otherwise specified
Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us